|
|
| | | | | | Dear colleagues,
| | | | | | | | On behalf of the entire ISHL13 team, we sincerely thank you for your attendance of the symposium. We are delighted that you have joined ISHL13 and hope you had a pleasant and informative conference.
| | | | | |
|
 |
| | | | | | We are confident that the data presented and discussed at ISHL13 will impact the field of Hodgkin lymphoma in the future. Highlights of the conference included presentations of data from the HD21 and SWOG S1826 trials on the treatment of older patients that indicated an unprecedented activity in this patient group. Additionally, the increasing knowledge on the prognostic role of circulating tumor DNA was mirrored by different abstracts.
| | | | | |
|
| | | | | | Recorded Sessions | | | | | | | | An E-mail with the password to access the videos has been sent to all participants.
| | | | | | | | | | | | | |
|
| | | | | | Your Feedback Matters | | | | | | | | As we have the ambition to continuously improve, we kindly ask you to participate in the evaluation of ISHL13. | | | | | | | | Do not hesitate to reach out to us if you have any further questions or feedback.
| | | | | | | | | | | | | |
|
| | | | | | We also express gratitude to our pharmaceutical partners for their support of ISHL13, their presence in the industrial exhibition and their satellite symposia.
 | | | | | |
|
| | | | | | We look forward to seeing you again at ISHL14 which will take place in autumn 2026.
| | | | | |
|
| | Kind regards,
| | | | | | | | Peter Borchmann, MD,
Symposium and GHSG Chairman | |
Sven Borchmann, MD/PhD,
Symposium Co-Chair | |
Paul J. Bröckelmann, MD,
Symposium Co-Chair | |
Dennis Eichenauer, MD,
Symposium Co-Chair | |
| | | | |
|
|
|
